Alzheimer's Drug Gets FDA Panel's Backing, Setting the Stage for Broader Use

US health advisers have unanimously backed the full approval of an Alzheimer's drug called Leqembi, which received preliminary approval earlier this year. Leqembi could slow Alzheimer's progression by several months and has associated side effects such as swelling of the brain and small bleeds in brain vessels. The final decision for full FDA approval will be made by July 6. If approved, Leqembi would be covered by insurance and Medicare, allowing patients with early stages of Alzheimer's to access the treatment. There are concerns about the cost and effectiveness of new plaque-targeting drugs like Leqembi, especially for Medicare recipients.